Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis ; volume:11 ; number:1 ; day:15 ; month:3 ; year:2018 ; pages:1-10 ; date:12.2018
Journal of hematology & oncology ; 11, Heft 1 (15.3.2018), 1-10, 12.2018
- Creator
-
Kvasnicka, Hans Michael
- Contributor
-
Thiele, Jürgen
Bueso-Ramos, Carlos E.
Sun, William
Cortes, Jorge
Kantarjian, Hagop
Verstovšek, Srdan
SpringerLink (Online service)
- DOI
-
10.1186/s13045-018-0585-5
- URN
-
urn:nbn:de:1111-201805244622
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kvasnicka, Hans Michael
- Thiele, Jürgen
- Bueso-Ramos, Carlos E.
- Sun, William
- Cortes, Jorge
- Kantarjian, Hagop
- Verstovšek, Srdan
- SpringerLink (Online service)
Other Objects (12)
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis